Makoto Jones1, Benedikt Huttner2, Molly Leecaster2, Angela Huttner2, Kavitha Damal2, Windy Tanner3, Christopher Nielson4, Michael A Rubin2, Matthew Bidwell Goetz5, Karl Madaras-Kelly6, Matthew H Samore2. 1. VA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA makoto.jones@va.gov. 2. VA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA. 3. University of Utah Department of Family and Preventative Medicine, Salt Lake City, UT, USA. 4. VA Reno Medical Center and University of Nevada Reno, Reno, NV, USA. 5. VA Greater Los Angeles Health Care System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 6. Clinical Pharmacy Service, Veterans Affairs Medical Center, Boise, ID, USA.
Abstract
OBJECTIVES: After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use. We investigated whether positive MRSA admission surveillance tests were associated with MRSA-positive clinical admission cultures and whether the availability of surveillance tests influenced prescribers' ability to match initial anti-MRSA antibiotic use with anticipated MRSA results from clinical admission cultures. METHODS: Analyses were based on barcode medication administration data, microbiology data and laboratory data from 129 hospitals between January 2005 and September 2010. Hospitalized patient admissions were included if clinical cultures were obtained and antibiotics started within 2 days of admission. Mixed-effects logistic regression was used to examine associations between positive MRSA admission cultures and (i) admission MRSA surveillance test results and (ii) initial anti-MRSA therapy. RESULTS: Among 569,815 included admissions, positive MRSA surveillance tests were strong predictors of MRSA-positive admission cultures (OR 8.5; 95% CI 8.2-8.8). The negative predictive value of MRSA surveillance tests was 97.6% (95% CI 97.5%-97.6%). The diagnostic OR between initial anti-MRSA antibiotics and MRSA-positive admission cultures was 3.2 (95% CI 3.1-3.4) for patients without surveillance tests and was not significantly different for admissions with surveillance tests. CONCLUSIONS: The availability of nasal MRSA surveillance tests in VA hospitals did not seem to improve the ability of prescribers to predict the necessity of initial anti-MRSA treatment despite the high negative predictive value of MRSA surveillance tests. Prospective trials are needed to establish the safety and effectiveness of using MRSA surveillance tests to guide antibiotic therapy. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
OBJECTIVES: After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use. We investigated whether positive MRSA admission surveillance tests were associated with MRSA-positive clinical admission cultures and whether the availability of surveillance tests influenced prescribers' ability to match initial anti-MRSA antibiotic use with anticipated MRSA results from clinical admission cultures. METHODS: Analyses were based on barcode medication administration data, microbiology data and laboratory data from 129 hospitals between January 2005 and September 2010. Hospitalized patient admissions were included if clinical cultures were obtained and antibiotics started within 2 days of admission. Mixed-effects logistic regression was used to examine associations between positive MRSA admission cultures and (i) admission MRSA surveillance test results and (ii) initial anti-MRSA therapy. RESULTS: Among 569,815 included admissions, positive MRSA surveillance tests were strong predictors of MRSA-positive admission cultures (OR 8.5; 95% CI 8.2-8.8). The negative predictive value of MRSA surveillance tests was 97.6% (95% CI 97.5%-97.6%). The diagnostic OR between initial anti-MRSA antibiotics and MRSA-positive admission cultures was 3.2 (95% CI 3.1-3.4) for patients without surveillance tests and was not significantly different for admissions with surveillance tests. CONCLUSIONS: The availability of nasal MRSA surveillance tests in VA hospitals did not seem to improve the ability of prescribers to predict the necessity of initial anti-MRSA treatment despite the high negative predictive value of MRSA surveillance tests. Prospective trials are needed to establish the safety and effectiveness of using MRSA surveillance tests to guide antibiotic therapy. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt Journal: J Clin Epidemiol Date: 2003-11 Impact factor: 6.437
Authors: Rajiv Jain; Stephen M Kralovic; Martin E Evans; Meredith Ambrose; Loretta A Simbartl; D Scott Obrosky; Marta L Render; Ron W Freyberg; John A Jernigan; Robert R Muder; LaToya J Miller; Gary A Roselle Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: Makoto Jones; Benedikt Huttner; Karl Madaras-Kelly; Kevin Nechodom; Christopher Nielson; Matthew Bidwell Goetz; Melinda M Neuhauser; Matthew H Samore; Michael A Rubin Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Paola Stano; Manuela Avolio; Rita De Rosa; Maria Luisa Modolo; Stefano M M Basso; Franco Lumachi; Alessandro Camporese Journal: In Vivo Date: 2012 May-Jun Impact factor: 2.155
Authors: Alexander J Kallen; Yi Mu; Sandra Bulens; Arthur Reingold; Susan Petit; Ken Gershman; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Priti R Patel; Scott K Fridkin Journal: JAMA Date: 2010-08-11 Impact factor: 56.272
Authors: Barbara Ellen Jones; Jian Ying; Vanessa Stevens; Candace Haroldsen; Tao He; McKenna Nevers; Matthew A Christensen; Richard E Nelson; Gregory J Stoddard; Brian C Sauer; Peter M Yarbrough; Makoto M Jones; Matthew Bidwell Goetz; Tom Greene; Matthew H Samore Journal: JAMA Intern Med Date: 2020-04-01 Impact factor: 21.873
Authors: Barbara E Jones; Makoto M Jones; Benedikt Huttner; Gregory Stoddard; Kevin Antoine Brown; Vanessa W Stevens; Tom Greene; Brian Sauer; Karl Madaras-Kelly; Michael Rubin; Matthew Bidwell Goetz; Matthew Samore Journal: Clin Infect Dis Date: 2015-07-29 Impact factor: 9.079
Authors: Joe S Matarlo; Yang Lu; Fereidoon Daryaee; Taraneh Daryaee; Bela Ruzsicska; Stephen G Walker; Peter J Tonge Journal: ACS Infect Dis Date: 2016-03-07 Impact factor: 5.084